Oric Pharmaceuticals (4TZ) Financial Statements
Oric Pharmaceuticals Financial Overview
Oric Pharmaceuticals's market cap is currently $854.70M. The company's EPS TTM is $-1.35; its P/E ratio is -6.84; Oric Pharmaceuticals is estimated to report earnings on November 9, 2026, and the estimated EPS forecast is $-0.34. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ -1.22M | $ -1.11M | $ -1.03M | $ 0.00 | $ 0.00 |
| Operating Income | $ -143.00M | $ -142.90M | $ -110.78M | $ -91.77M | $ -78.87M |
| EBITDA | $ -128.25M | $ -126.74M | $ -99.67M | $ -85.80M | $ -77.82M |
| Net Income | $ -129.47M | $ -127.85M | $ -100.70M | $ -89.12M | $ -78.72M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 281.49M | $ 255.96M | $ 208.19M | $ 206.27M | $ 236.98M |
| Total Assets | $ 411.00M | $ 274.14M | $ 254.69M | $ 250.36M | $ 298.64M |
| Total Debt | $ 11.55M | $ 3.18M | $ 10.21M | $ 12.10M | $ 1.93M |
| Net Debt | $ -34.12M | $ -56.22M | $ -13.17M | $ -54.74M | $ -224.08M |
| Total Liabilities | $ 26.64M | $ 31.02M | $ 30.60M | $ 28.01M | $ 25.67M |
| Stockholders' Equity | $ 384.36M | $ 243.12M | $ 224.09M | $ 222.35M | $ 272.98M |
| Cash Flow | |||||
| Free Cash Flow | $ -114.08M | $ -113.85M | $ -86.54M | $ -77.22M | $ -60.48M |
| Operating Cash Flow | $ -110.97M | $ -112.66M | $ -85.69M | $ -75.14M | $ -59.54M |
| Investing Cash Flow | $ -148.03M | $ 22.14M | $ -43.40M | $ -109.25M | $ 158.44M |
| Financing Cash Flow | $ 245.26M | $ 126.55M | $ 85.66M | $ 25.23M | $ 49.13M |
Currency in USD